From PRA Health Sciences, Salt Lake City, Utah.
Accepted for publication August 18, 2017.
Funding: Within the past 36 months, L.R.W. has received honorarium or travel expenses or served in an advisory capacity for the following companies: AcelRx Pharmaceuticals, Acura Pharmaceuticals, AstraZeneca, BioDelivery Sciences International, Boehringer Ingelheim, Bristol-Myers Squibb (BMS), Cara Therapeutics, Charleston Labs, Collegium Pharmaceuticals, CVS Caremark, Depomed, Egalet, Grunenthal USA, Inspirion Pharmaceuticals, Insys Therapeutics, Jazz Pharmaceuticals, Kaleo Pharmaceuticals, Mallinckrodt, Marathon Pharmaceuticals, Medtronic, Merck, Nektar Therapeutics, Neura Therapeutik, Nevro Corporation, Orexo Pharmaceuticals, Pfizer, Proove Biosciences, QRx Pharma, Quintiles, Shionogi, Signature Therapeutics, TEVA, Theravance, Trevena, and Zogenix.
The author declares no conflicts of interest.
Reprints will not be available from the author.
Address correspondence to Lynn R. Webster, MD, PRA Health Sciences, 3838 S 700 E, Suite 202, Salt Lake City, UT 84106. Address e-mail to [email protected].